Karyopharm reports third quarter 2022 financial results and highlights recent company progress

– achieved third quarter 2022 total revenue of $36.1 million, including xpovio® (selinexor) net product revenue of $32.0 million, a 20 % increase over third quarter 2021– – initiated phase 3 study evaluating selinexor as a maintenance therapy in women with advanced or recurrent tp53 wild-type endometrial cancer – –encouraging data observed in phase 1 study of selinexor in combination with ruxolitinib in treatment-naÏve myelofibrosis, including activity across three key efficacy endpoints, and a generally manageable safety profile with no dose limiting toxicities. updated results to be presented at ash – – company re-affirms full year 2022 xpovio net product revenue guidance of $120 million to $130 million, total revenue guidance of $155 million to $165 million and cash runway into early 2024 – – conference call scheduled for today at 4:30 p.m.
KPTI Ratings Summary
KPTI Quant Ranking